Apart from reducing systemic lipid levels,statins mayi mprove the clinical course of atherosclerosis by exerting favourable pleiotropiceffects on the vesselwall.Westudiedthe effects of rosuvastatin, an ew,p otent 3-hydroxy-3-methylglutaryl coenzyme A( HMG-CoA)r eductasei nhibitor,onv ascular remodellinga fter endotheliali njuryi nt he hyperlipidaemica polipoproteinE -knockout (apoE-/-) mouse.A poE-/-mice, 22-weeks-old,wereinjected daily with rosuvastatin at alow (1 mg/kg;n=27) or highd osage (10 mg/kg;n=24), or withv ehicle alone (n=26).Aftertreatment for2weeks,endothelialinjuryand thrombosis of the carotid artery was induced with 10% ferric chloride.Tr eatment was thenresumed fora3-week period.Althoughstatin treatment did not affectthe plasma lipid levels of mice, mean timestoarterial thrombosis were prolonged in the low-dose andt he high-dose groupc ompared to controls Keywords Animalmodels, atherosclerosis, tissuer emodelling, fibrinogen/ fibrin, restenosis ( P <0.05 and P <0.01 respectively).I nterestingly, rosuvastatin withdrawal 4d aysb eforei njuryc ompletelyr eversedt he antithrombotic effects of the drug. In follow-up studies 3w eeks after injury, deposition of fibrin in the vesselwall was significantly reducedi nt he rosuvastatin-treateda nimals. Therew as an increase in the content of α -actin-positives mooth musclec ells ( P =0.008) and collagen fibers ( P <0.001),and aconcomitantdecrease in the number of oxLDL-containing macrophages ( P <0.001).Overall, theneointimalareaand the severityofluminal stenosis were significantlyr educed in statin-treatedm ice. Thus,rosuvastatinattenuatesarterial thrombosis and neointima formation,and it maystabilise vascular lesions developing after endothelialinjuryinmice.These effects areindependent of systemiclipid lowering.
Introduction
Large-scale clinicaltrials have consistentlydemonstrated the efficacyof3-hydroxy-3-methylglutaryl coenzyme A(HMG-CoA) reductase inhibitors (statins)inthe primaryand secondaryprevention of cardiovasculardiseasedue to atherosclerosis and its complications (1) .According to the prevailing hypothesis, which has provided the basis for current clinicalrecommendations (2) , the reduction in the rate of cardiovascular eventsi np atients treated with statins is largelyattributedtothe potent lipid-lowering effectsofthese drugs. Interestingly, data from in vitro studies suggest thatstatins mayalso exertpleiotropic favourableeffects on endothelial cells,smooth muscle cells and monocytes (3) , and that theym ay modulate inflammatorya nd immune responses (4) .However,the implications of these findings for human disease remain uncertain ( 5) , despite the accumulating evidence thatthe clinicalbenefits of statin treatment are notconfined to patients with elevatedcholesterol levels (6, 7) .
Apolipoprotein E-knockout(apoE-/-) miceare characterised by markedlyelevatedplasma cholesterol and triglyceride levels whichare notreduced by short-term (8) or long-term(9) statin treatment. Therefore, the apoE-/-mouse maybeapowerful tool for dissecting the (possible)pleiotropic effectsofstatins on vascular homeostasis and,p articularly, on atherogenesis and the wound healing process after injury. In ones tudy,t reatment of apoE-/-m icew ith simvastatin reduced aortic atherosclerosis (quantified through the measurement of aortic cholesterol content) apparentlywithoutaffecting lesion histology (9) , while another study found an increase of innominate/brachiocephalic artery atherosclerosis, butreported amore "favourable" lesion his-tology with reduction in intraplaque haemorrhage and calcification (10) . Finally, athird study reported areduction of atherosclerosis (aortic plaque area) in LDLreceptor-knockoutmiceas opposed to an increase in plaque size in their apoE-knockout counterparts placed on high-doses imvastatin treatment (11) . Technical difficultiesinstandardisation of mouseatherosclerosis as well as the different statindosage and localisation of the vessels studiedw ere probably responsible, at leasti np art, for these seeminglyinconsistent findings, as theywere, forexample, in previous studies whichattemptedtoclarify the roleoffibrinolytic factorsinatherosclerosis (12) (13) (14) .
Atherothrombosis is not onlyacomplication of plaque rupture,b ut also an important pathomechanism of atherosclerosis progression (5) . In fact,thrombosis and thrombus organisation appear to be keyevents in vascularwallinflammation and the response to endotheliali njury (15) (16) (17) . Although experimental models of arterial injurya nd thrombosis cannot exactly reproduce the pathophysiologyo fh uman atherosclerosis, we and othersh avep reviouslys hown that the ferric chloride modelo f carotid artery injuryr esults in ar eproduciblet hrombotic reaction and the subsequent formation of neointimallesions which exhibit several histological characteristics of humanatherosclerotic plaques ( 18, 19) . Therefore, in the present study,w ee mployedthe ferric chloride modelinapoE-/-mice in ordertostudy the effectso fr osuvastatin, an ew,p otent HMG-CoA reductase inhibitor (20) ,onthe vascularremodelling process. Our hypothesis wasthat rosuvastatin directly(i.e., independent of its lipidlowering properties) modulatesthrombosis and the ensuing inflammatoryresponse, and thatthese effects might contribute to a reduction in the sizeand an increase in the stability of neointimal lesions developinginmiceafter endothelialinjury.
Materials andmethods

Rosuvastatintreatment and arterial injury in vivo
Male and femalea polipoprotein E-knockout (apoE-/-)m ice were purchased from JacksonL aboratories( BarH arbor,M E, USA). After weaning at the age of 3-4w eeks,m icew ere fed regularrodent chow. At theage of 18 weeks,micewere divided into three treatment groups. The first (control) group (n=26; 12 male, 14 female) received 100mLnormal saline (vehicle),the second group (n=27; 14 male, 13 female) wastreated with rosuvastatin at alow dosage (1 mg/kg body weight (BW) in 100 mL normalsaline), and the third(n=24; 14 male, 10 female) received ahigh dosage of rosuvastatin (10 mg/kg BW). Rosuvastatin or vehicle wasgiven to miceonce dailybyintraperitoneal injection. The investigatorsp erforming the in vivo experiments, and the plateleta ggregation and immunohistochemical studies( described below) were blindedtothe type of treatment.
After twoweeks of treatment, micewere anaesthetisedbyintraperitoneal injection of xylazine/ketamine and subjected to carotid artery injuryusing ferric chloride according to astandardisedprotocol (18, 21) . Briefly,the leftcarotid artery of the anaesthetised mouse wascarefullyexposed by blunt dissection, and a 0.5 x1.0-mm strip of Whatman no. 1filterpaper soakedin10% FeCl 3 solution wasapplied to the surfaceofthe vesselfor 3min-utes. Carotid blood floww as monitored before and over a 30-minute period after the injuryusing an ultrasound flow probe (0.5 VB,Transonic Systems) interfaced with aflowmeter(T106, Transonic Systems) and ad ataa cquisition program (WinDaq Lite,DATAQ Instruments).Complete thromboticocclusion was consideredtooccur when flow decreasedto0.0 ±0.2 ml/min according to the manufacturer'sspecifications.After injury, treatment wasc ontinued over a3 -week period,i .e. throughout the vascularhealing process (15) .
In ordertostudy the effectsofacutestatin withdrawal on arterial thrombosis after endotheliali njury in vivo,a na dditional group of 18-week-old apoE-/-mice (n=12) received rosuvastatin at ahigh dosage (10mg/kg) for 2weeks.Subsequently, rosuvastatin treatment waswithdrawnand mice were subjected to carotid artery injurywith ferricchloride 4dayslater under exactly the same experimental conditions as describedabove.
All animal careand experimental procedures were approved by the AnimalResearch Committeeofthe University of Goettingenand complied with national guidelines and the Guide for the Care and Use of LaboratoryA nimals published by the NationalI nstitutes of Health (NIH Publication No. 85-23, revised 1996).
Body weight and metabolic plasma parameters
Mice were weigheddaily from the beginning of rosuvastatin(or vehicle) treatment at 18 WOAuntil completion of the study at the age of 23 weeks.Att he timeo fs acrifice, blood wasc ollected from deeplyanaesthetised mice by cardiacpuncturein3.8% sodium citrate (final dilution). Plasma waso btained by centrifugation at 3,000rpm for 5minutes. Plasma totalcholesterol, LDL and HDL cholesterol, and triglyceride levels were determined enzymatically (Sigma) (18) . Morphometric and histochemical analysis of neointima Fort issue harvesta nd processing, anaesthetised animals were carefully perfusion-fixed with 4% zinc formalin through the left ventricle.The carotid arteryi ncluding the bifurcation wase xcised, post-fixed in 4% zinc formalin, dehydrated and embedded in paraffinwax.
Form orphometric analysis, paraffin-embedded carotid artery sections were stained with Ve rhoeff'selastic stain and analysed(ImagePro Plus; MediaCybernetics).Fivesections equally spaced throughoutt he injured segment (at2 00-μ mi ntervals) were evaluateda nd the resultsw ere averaged fore ach animal (15, 18, 22) . Groups of 18 to 21 animals were compared.
Interstitialc ollagen wasd etected by picrosirius redp olarisation microscopy ( 22, 23) . Immunohistochemistryw as performedo n5μ m-thickp araffins ections as described (15, 22) . Smoothmuscle cells (SMC)w ere detected using amonoclonal anti-mouse α -actinantibody (HRP-labeled; Dako)followedb y incubation with aminoethyl-carbazole( AEC)r eagent( Zytomed). Macrophages were identifiedu sing ar at anti-mouse Mac-3 antibody( PharMingen), and fibrinogen wasl ocalised with ar abbit anti-humanfibrinogena ntibody (Dako). Finally, oxidisedL DL wasd etected using an antibodya gainst murine malondialdehyde (MDA)-conjugatedL DL (kind gift of Dr.W . Palinski, University of California,San Diego, CA, USA) and an avidin-biotin phosphatased etection system( Universal APAAP kit; Dako).
To quantitatively assess the presence of macrophages in the vesselw all, the area of the arterial wall (within the external elastic lamina)staining positive for Mac-3 antigenwas expressed as percentage of the total area within the external elastic lamina.S imilarly, the relativea rea of the arterial wall positive for α -actin, oxLDL, fibrinogen and collagenwas determinedbydividingthe positivelystainedarea by the totalarea using the computer morphometrysystem (22) .
In vitro platelet aggregation
Preparation of platelet-rich plasma( PRP) and platelet aggregation studieswere performed as previously described (24) . For each experiment, blood waspooled from five to six animals that had beent reated with low-doseo rh igh-doser osuvastatin, or with vehicle, for 14 days. As tandard platelet concentration of 5x10 7 /ml wasused, and aggregation experiments were performed on amicroplate reader.Briefly, a5-mLvolume of ADP solution at variousconcentrations (0.01 μ Mto10 μ M) wasplaced in each well, followedb ythe addition of 95 μ Loffreshly prepared PRP. Changes in light transmission over time were expressed as percentage of platelet-poor plasma (PPP) light transmission, with transmission of untreatedPRP serving as the zero standard.All experiments were performed in triplicate. Standard software programs were used to constructaggregation traces.
Statisticalanalysis
Comparisons between means of treatment groups were performed using the Kruskall-Wallis non-parametrict estf ollowedb y Dunn's multiple comparison test. Forc omparisons of proportions,Fisher'sexacttestwas used. Allstatistical tests were twosidedwith a P value of <0.05 indicating statisticalsignificance.
Results
Effectsofstatintreatment and statinwithdrawal on arterial thrombosis in vivo
In agreementwith previous reports(9, 10), treatment with rosuvastatin over a5-week period (from the 18 th to the 23 rd WOA) did not significantly alterbody weight or plasma cholesterol or triglyceride levels in the apoE-/-mice(Table1). After induction of carotid artery injury, thrombotic occlusion failedtooccur in 4of 26 mice (15%)i nt he control group comparedt o8o f2 7m ice (30%) in the low-doserosuvastatin group ( P =0.36 vs. controls) and 9o f2 4m ice( 38%) in the high-dose group ( P =0.15). The meant ime to thrombotic occlusion wasd ose-dependentlyp rolonged under rosuvastatin treatment, increasing from 14.2± 1.1 minutes (median, 11.6) in the control group to 17.5±1.0 minutes (median, 15.5) in the low-dose ( P <0.05) and 18.4±1.2 minutes (median, 16.2) in the high-dose group ( P <0.01; Fig. 1A ).Atthe end of the 30-minute flowmonitoring period after injury, vascular patency (including both the vessels thatnever occluded and thoset hat recanalised after thrombotico cclusion) was3 9% (10/26 injured vessels) in control mice, as opposedt o5 9% (16/27) in the low-dose ( P =0.22) and 67% (16/24) in the highdose group ( P =0.08; Fig. 1B) . Thus, rosuvastatin treatment appearedtoattenuate the thrombotic response of mousevessels to endotheliali njuryb yd elaying and/or preventing thrombus formation, and by enhancing thrombus resolution and arterial recanalisation.
In furtherexperiments, carotid injurywas induced in mice4 days after withdrawalo fh igh-doser osuvastatin treatment. In these studies, the percentage of non-occludedv essels wasr educed from38% in the high-dose group to 17% in the withdrawal group ( P =0.27). Furthermore,the times to thrombosis after statin withdrawal(15.2±4.8 minutes; median, 13.4) were no longer significantlyd ifferent from thosei nv ehicle-treated mice ( Fig.  1A) .F inally, only2o f1 2m ouse carotid vessels (17%)i nt he withdrawalgroupwere patent 30 minutesafter injury, asignificantly lowerp roportion compared to rosuvastatin-treated mice ( P =0.018 vs. the low-dose and 0.012 vs. the high-dose group), and slightlyl ower compared to the control group (Fig. 1B) . These resultssuggestedthat acute withdrawalofhigh-doserosuvastatin before induction of endotheliali njuryc ompletelyr eversed the antithrombotic effectsofthe drug.
Rosuvastatinmodulatesplatelet aggregation in vitro
We examinedw hethert he effects of rosuvastatin on arterial thrombosis were mediatedbyits effectsonplateletfunction. Platelet-richplasma wasisolated from apoE-/-micethat had been treated with rosuvastatino rw ith vehicle alone for 2w eeks. Maximum plateleta ggregation (i.e.,t he maximum change in light transmission expressed as percentage of PPPl ight transmission)i nr esponset oh igh concentrations of ADP( 10 mM) wass ignificantly decreasedi nm icet reated with low-dose (24.3%) and particularlyw ith high-dose rosuvastatin( 7.8%) comparedt oc ontrol mice (38.9%; P <0.001 for both comparisons; not shown).
Rosuvastatintreatment reducesneointimal growth afterinjury
After injury withferricchloride, apoE-/-mice continued to receive rosuvastatino rv ehicleb yi ntraperitoneal injection once dailyfor 3weeks.Atthe end of that period,the effects of rosuvastatin treatment on neointimal growth were quantifiedboth haemodynamically and histochemically. Doppler flowstudiesofanaesthetised mice prior to sacrifice and tissue harvest showedthat all (100%)injuredcarotid vessels in the 3treatment groups were
Figure2:Neointimal growth after arterialinjuryinapoE-/-mice is reducedb y rosuvastatin treatment in adose-dependent manner. Displayedare representative sections of carotidvessels harvested 3 weeks after injuryand stainedwithVerhoeff's elastic stain. Arrows denote theinternal elastic lamina. Magnification, x400 (left panels); and x1000 (right panels). patent(not shown),indicating the absence of residual occluding thrombus. However, Ve rhoeff'se lastic stain of paraffin-embeddedarterial sections revealed thatdaily treatment with rosuvastatin at eitherthe low(1mg/kg) or the high (10 mg/kg) dosage reducedt he area of the neointima butn ot that of the media in apoE-/-mice (Fig. 2) . Quantitative morphometric analysis confirmed these findings by demonstrating asignificant reduction of the intima-to-mediaratio from 0.42±0.03 in the control group to 0.30±0.03 in the low-dose and 0.30±0.05 in the high-dose rosuvastatin group (Fig. 3A) .Inaddition, the severity of luminal stenosis resulting from neointimal growth wassignificantly decreased in both the low-dose (21.3±1.9%) and the high-dose rosuvastastingroup(22.3±2.9%) comparedtothe vehicle-treated mice(32.3±2.4%; Fig. 3B ).
Effectsonthe compositionofvascularlesions
Quantitative immunohistochemical analysis of the neointima and media demonstrated thatrosuvastatin treatment at the time of injurya nd throughout the 3-weekv ascular wound healing period wasa ssociatedw ith reduced fibrin(ogen) deposition in the vesselw all. This effect wasp articularlyp ronounced in the high-dose group, butitwas alreadysignificant in micereceiving 1mg/kg rosuvastatin daily (Fig. 4 , A-C; quantitative analysis in D).Interestingly, the reduction in intramural fibrinogen wasnot accompanied by changes in the protein expression of plasminogen activator inhibitor-1 or tissue factor (not shown). Further immunohistochemical studiesr evealed ar eduction in Mac-3-immunopositive area from7 0.8±5.5% in the control group to 65.5±7.9% in the low-dose and 42.4±9.8% in the highdose group. This finding reflectedareduction in the number of Mac-3-positive macrophages in the vesselwall(not shown).Importantly, sincemost of these cells were identifiedasfoam cells whichs tainedp ositivef or oxLDL, rosuvastatinw as also dosedependentlyassociatedwith areduction in the oxLDL-positive area in the vesselwall (Fig. 5 , A-C; analysis in D) (21) .Finally, statin treatment wasa ccompaniedb ya ni ncrease both in the smoothmuscle cell content (from 5.2±0.7% in the control group to 8.2±2.1% in the low-dose and 11.8±2.4% in the high-dose group; P =0.008 and P <0.001, respectively)and in the collagen content (from 4.8±2.4%inthe control group to 6.2±0.9% in the low-dose and 12.9±1.7% in the high-dose group; P =0.26 and P <0.001, respectively)ofarterial lesion ns developing3w eeks after injury(not shown).
Discussion
Studies on humana therosclerosiss uggest that treatment with statins not onlyreduces the sizeoflesions and the thickness of the arterial wall, butthat it mayalso contribute to plaque stabilisation by decreasing lipidcontent, inflammation and matrix proteolysis while increasing collagencontent (25, 26) . These observations,w hich arei na greement with the results obtainedi na rabbit modelofh yperlipidaemia and atherosclerosis (27) ,have largelybeen attributedtothe establishedlipid-lowering effects of statins in humans and most animalmodels. In fact,dietary lipid lowering results in histological changes,s imilart ot hose described after statin treatment (23, 27) , and the physiological importanceo ft he so-called pleiotropic effects of statins on the vesselwallremains speculativetodate (5) . Convincing evidence for the presence of direct anti-atherosclerotic (i.e. anti-inflammatoryand plaque-stabilising) effects of statins independent of systemic lipidl owering could have enormous clinicali mplications,sinceitmight extend the use of these drugs to primary prevention of cardiovasculard iseasei nal arge population of high-and intermediate-risk normolipidaemic individuals (28) .
In vivo models for systematically analysing the effectsofstatin treatment on vascularbiology have thus farfocusedeitheron strokeprotection followingligation of the middle cerebral artery (29, 30) , or on neointimal growth after mechanical (wire-or balloon-induced) injurytothe carotid artery (31, 32) . In the present study,weusedthe ferric chloride modelofcarotid artery injury whichr eproduciblyi nducest he formation of platelet-richo ccluding thrombi with subsequent fibrin deposition, thrombus organisation and neointimal formation (15, 21, 22) . As this sequenceo fe vents partlyr eproduces critical pathophysiological stepsi na therosclerosisa nd atherothrombosis (16),w ea nticipatedthat the ferric chloride modelmight allowustostudy the effectso fs tatin treatment on variousc ellt ypes including platelets, endothelial cells,smooth muscle cells, and macrophages. In agreementwith previous observations in apoE-/-and LDL-re- ceptor-knockoutmice(9, 10, 31) and in contrast to recentlyreported studiesinapoE3*-Leidentransgenic mice(33), we found no significant effectsofrosuvastatin treatment on body weight or the lipid profile of mice. Despite the persistence of hypercholesterolaemia, ak nown potent stimulus of plateleta ggregation and thrombosis (18) , our in vivo experiments revealed thatrosuvastatin treatment significantly attenuatedt he thromboticr esponse of apoE-/-m icet oa rterial injuryi nad ose-dependent manner. These results were associated with areduction in the in vitro aggregation of platelet-rich plasmaf rom rosuvastatintreated miceinresponsetoADP.Our findings thus extend previousobservations in normocholesterolaemicmice (34) and add further supporttothe hypothesis that statins possess important antithromboticp ropertiesw hich maye xtend beyond antagonisation of the prothrombotic effects of hypercholesterolaemia (35, 36) . In this regard,itislikelythat statins maydirectly inhibit plateletactivation by upregulating endothelial nitric oxide synthase in these cells (34) . Importantly,the protective effectsofstatins on plateletfunction maybereversed 2-4daysafter acutestatin withdrawal (37) ,a nd we could in fact showi nt he present study that abrupt cessation of rosuvastatin treatment resulted in complete restoration of the thromboticresponsetoinjuryand the fast formation of stable, lysis-resistant arterial thrombi. At present,itremains to be determinedwhetherstatin withdrawal in patients with acutecoronary syndromesmay significantlyincrease the risk for cardiovascularmorbidity and mortality (38) .
Followinginduction of arterial injury, low-doseorhigh-dose rosuvastatin( or vehicle) treatment wasc ontinued in our study throughout the 3-weekwound healing period (21) .Inagreement with arecent reportinLDL-receptor-knockout mice (31) ,statin treatment reduced the sizeo fv ascular lesions( i.e.t he intimamedia ratio and the severity of luminalstenosis) developingafter injury. These effects, whichw ere alreadys ignificant at low( 1 mg/kg)dosagesofrosuvastatin, maybeassociatedwith accelerated reendothelialisation followingm obilisation and incorporation of bonem arrow-derivede ndothelial progenitor cells (EPCs) (32, 39) . Of note, an increase in the number of circulating EPCsunder statin treatment has also beenobservedinpatients with coronarydisease (40) , emphasizing that the potential role of EPCsinthe pathophysiologyofthe vascularresponsetoinjury deserves further investigation.Alternatively, or in addition to this mechanism, our resultsmay be due to the significant reduction of thrombus sizeand subsequent fibrin deposition in the vessel wall of rosuvastatin-treated mice. In fact,w ea nd othersh ave shown thatc ertain injurym odels, including the ferric chloride modelusedinthe present study,are characterised by amarked thrombotic reaction and fibrin deposition in the arterial wall (21, 41, 42) . In these models and in human atherosclerosis (15, 16) , organising thrombus mayprovide an important provisional matrix for cell migration and neointimalgrowth.
Af urther finding of our study wast hat dailyr osuvastatin treatment during the vascularr emodelling processn ot onlya ffected lesion sizebut also reducedthe accumulation of oxLDLladen macrophages (foamc ells) and increased the α -actin (smooth muscle cell) and collagenc ontent of the plaquesi na dose-dependent manner. These results add to the evidencesupporting the anti-inflammatorya nd plaque-stabilising effects of statins in vivo (10, 26, 27, 33) and also suggest that, at least in the mouse, these effects areindependent of systemic lipidlowering. Of note, previous studies demonstrated that statins attenuated the proliferation of culturedsmooth cells by interferingwith Gprotein-mediatedcellcycle regulation (43) and raised fearsthat areduction in the smooth muscle cellpopulation might contribute to plaque destabilisation and rupture.H owever,t his concerni s probablynot justified in the clinicalsetting (5), since the concentrations of statins required to inhibit smooth muscle cellproliferation in vitro are rarely, if ever,achieved in vivo.Infact,our results supportthe thesis that the beneficial anti-inflammatoryeffects of statins are thosethat predominate and contribute to increased plaque stability following vascularinjury in vivo.
We also found thatt he change in composition of vascular lesionsi nr osuvastatin-treated apoE-/-mice wasn ot accompaniedbyadecreaseinthe localexpression of plasminogen activator inhibitor-1 or tissue factor.This finding wasunexpected in light of previous in vitro data (44, 45) . Moreover,i tw as recently reported thata dministration of simvastatin foru pt o2 4 weeks reduced tissue factor expression in atherosclerotic plaquesofapoE-/-mice (46) .The explanation for the apparent discrepancybetween this latterstudy and ourown results maybe the differences in the type and dosage of statin used, the duration of treatment, and,p articularly, the type of vascularl esions studied( i.e., spontaneously developinga therosclerotic plaques vs. neointimal lesions after ferric chloride-induced endothelial injury).C learly, caution is warranted when extra-polating in vitro effectsofstatins on cultured endothelialorsmooth muscle cells to pathophysiological processes in vivo and particularlyto human disease. It also needs to be mentioned that experimental mouse models of atherosclerosis and/or arterial injury, including the ferricc hloride model used in the present study,c annot exactly reproduce the pathophysiology of humana therosclerosis, atherothrombosis, or restenosis. Notwithstanding this limitation, lesionsdeveloping in miceafter injurywith ferricchloride exhibit several histological characteristics of humanatherosclerotic plaques (15, 19) , and their systematic study helps dissect basic pathomechanisms of the vascularw ound healing (remodelling) process in the presenceofcardiovascularrisk factorssuch as hyperlipidaemia (18) .
In conclusion,our studies in apoE-/-mice reveal thatrosuvastatin attenuatesp lateleta ggregation and the thrombotic response to endothelialinjury, reduces neointimalgrowthand the size of vascularlesions,and favourablyalters the composition of plaquesb yr educing fibrin deposition and foamc ella ccumulation while increasing smooth muscle celland collagencontent. Since these effects were notassociatedwith aconcomitant improvement in the lipid profile of mice, ourresults strengthenthe existing experimental evidencefavouring the pleiotropic effects of statins on thrombocytes and the vesselwall, and theythus supportthe needfor clinicaltrials to test the benefits of statins in the primary prevention of cardiovascularevents in appropriatelyselected normolipidaemic individuals.
